Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Mounting evidence suggests that inhibition of protein phosphatase-2A (PP2A), a serine/threonine phosphatase, could enhance anticancer immunity. However, drugs targeting PP2A are not currently available. Here, we report that a PP2A inhibitor, LB-100, when combined with anti-PD-1 (aPD-1) blockade can synergistically elicit a durable immune-mediated antitumor response in a murine CT26 colon cancer model. This effect is T-cell dependent, leading to regression of a significant proportion of tumors. Analysis of tumor lymphocytes demonstrates enhanced effector T-cell and reduced suppressive regulatory T-cell infiltration. Clearance of tumor establishes antigen-specific secondary protective immunity. A synergistic effect of LB-100 and aPD-1 blockade is also observed in B16 melanoma model. In addition, LB-100 activates the mTORC1 signaling pathway resulting in decreased differentiation of naive CD4 cells into regulatory T cells. There is also increased expression of Th1 and decreased expression of Th2 cytokines. These data highlight the translational potential of PP2A inhibition in combination with checkpoint inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)
Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390
Phosphatase PP2A is requisite for the function of regulatory T cells
Apostolidis, S. A., Rodríguez-Rodríguez, N., Suárez-Fueyo, A., Dioufa, N., Ozcan, E., Crispín, J. C., Tsokos, M. G., & Tsokos, G. C. (2016) · Nature Immunology · doi:10.1038/ni.3390 · Cited by 238
In vivo discovery of immunotherapy targets in the tumour microenvironment
Zhou, P., Shaffer, D. R., Alvarez Arias, D. A., Nakazaki, Y., Pos, W., Torres, A. J., Cremasco, V., Dougan, S. K., Cowley, G. S., Elpek, K., et al. (2014) · Nature · doi:10.1038/nature12988 · Cited by 237
Lecca, S., Pelosi, A., Tchenio, A., Moutkine, I., Lujan, R., Hervé, D., & Mameli, M. (2016) · Nature Medicine · doi:10.1038/nm.4037 · Cited by 176
mTOR Signaling, Tregs and Immune Modulation
Chapman, N. M., & Chi, H. (2014) · Immunotherapy · doi:10.2217/imt.14.84 · Cited by 148
Research works printed but not linked: 33
- Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015). · DOI · Paper page
- Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010). · DOI · Paper page
- Taffs, R. E., Redegeld, F. A. & Sitkovsky, M. V. Modulation of cytolytic T lymphocyte functions by an inhibitor of serine/threonine phosphatase, okadaic acid. Enhancement of cytolytic T lymphocyte-mediated cytotoxicity. J. Immunol. 147, 722–728 (1991). · doi:10.4049/jimmunol.147.2.722
- Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 25, 9543–9553 (2005). · DOI · Paper page
- Kingwell, K. Cancer: live screening of immunotherapy targets. Nat. Rev. Drug Discov. 13, 258 (2014). · DOI
- Delgoffe, G. M. PP2A’s restraint of mTOR is critical for T(reg) cell activity. Nat. Immunol. 17, 478–479 (2016). · DOI
- Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539–543 (2016). · DOI · Paper page
- Janssens, V. & Rebollo, A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr. Mol. Med. 12, 268–287 (2012). · DOI · Paper page
- Chung, V. et al. Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase-2A, in patients with relapsed solid tumors. Clin. Cancer Res. 23, 3277–3284 (2016). · DOI · Paper page
- Hong, C. S., Ho, W., Zhang, C., Yang, C., Elder, J. B. & Zhuang, Z. LB-100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol. Ther. 16, 821–833 (2015). · DOI · Paper page
- Gordon, I. K. et al. Protein phosphatase 2A inhibition with LB100 enhances radiation-induced mitotic catastrophe and tumor growth delay in glioblastoma. Mol. Cancer Ther. 14, 1540–1547 (2015). · DOI
- Ho, W. S. et al. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget 7, 12447–12463 (2016). · DOI
- Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y. & Levy, R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl Acad. Sci. USA 112, E966–972 (2015). · DOI · Paper page
- Ho, W. S. et al. LB-100, a novel protein phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett. 415, 217–226 (2018). · DOI
- Melero, I., Rouzaut, A., Motz, G. T. & Coukos, G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 4, 522–526 (2014). · DOI · Paper page
- Kroesen, B. J., Mesander, G., ter Haar, J. G., The, T. H. & de Leij, L. Direct visualisation and quantification of cellular cytotoxicity using two colour flourescence. J. Immunol. Methods 156, 47–54 (1992). · doi:10.1016/0022-1759(92)90009-i
- Lu, J. et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc. Natl Acad. Sci. USA 106, 11697–11702 (2009). · DOI · Paper page
- Chang, K. E. et al. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Mol. Cancer Ther. 14, 90–100 (2015). · DOI
- Bai, X. et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1alpha-VEGF mediated angiogenesis. Cancer Lett. 355, 281–287 (2014). · DOI
- Bai, X. L. et al. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol. Cancer Ther. 13, 2062–2072 (2014). · DOI
- Wei, D. et al. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin. Cancer Res. 19, 4422–4432 (2013). · DOI
- Haxhinasto, S., Mathis, D. & Benoist, C. The AKT-mTOR axis regulates de novo differentiation of CD4+ Foxp3+ cells. J. Exp. Med. 205, 565–574 (2008). · DOI · Paper page
- Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295–303 (2011). · DOI · Paper page
- Sukari, A., Nagasaka, M., Al-Hadidi, A. & Lum, L. G. Cancer immunology and immunotherapy. Anticancer Res. 36, 5593–5606 (2016). · DOI
- Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015). · DOI · Paper page
- Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389–1402 (2013). · DOI · Paper page
- Kiely, M. & Kiely, P. A. PP2A: the wolf in sheep’s clothing? Cancers 7, 648–669 (2015). · DOI · Paper page
- Zhang, M., Yogesha, S. D., Mayfield, J. E., Gill, G. N. & Zhang, Y. Viewing serine/threonine protein phosphatases through the eyes of drug designers. FEBS J. 280, 4739–4760 (2013). · DOI
- Li, Y. M., Mackintosh, C. & Casida, J. E. Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Inhibitor specificity of cantharidin and ATP analogues. Biochem. Pharmacol. 46, 1435–1443 (1993). · DOI
- Gehringer, M. M. Microcystin-LR and okadaic acid-induced cellular effects: a dualistic response. FEBS Lett. 557, 1–8 (2004). · DOI
- Falconer, I. R. & Humpage, A. R. Preliminary evidence for in vivo tumour initiation by oral administration of extracts of the blue-green alga cylindrospermopsis raciborskii containing the toxin cylindrospermopsin. Environ. Toxicol. 16, 192–195 (2001). · DOI
- Rossini, G. P., Sgarbi, N. & Malaguti, C. The toxic responses induced by okadaic acid involve processing of multiple caspase isoforms. Toxicon 39, 763–770 (2001). · DOI
- Yatsunami, J., Komori, A., Ohta, T., Suganuma, M., Yuspa, S. H. & Fujiki, H. Hyperphosphorylation of cytokeratins by okadaic acid class tumor promoters in primary human keratinocytes. Cancer Res. 53, 992–996 (1993).
Cited by
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Self-citationSelective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
“…yet underexplored strategy lies in the activation of phosphatases (Allen-Petersen et al., 2019; Cristóbal et al., 2015; Gutierrez et al., 2014; Ho et al., 2018; Kauko et al., 2018; Neviani et al., 2007; Rincón et al., 2015; Sangodkar et al., 2017; Switzer et al., 2011; Tohmé et al.,…”
BackgroundPP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93
Targeted protein modification as a paradigm shift in drug discovery
Amirian, R., Azadi Badrbani, M., Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S. M., Derakhshankhah, H., & Jaymand, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115765 · Cited by 18
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Ho, W. S., Wang, H., Maggio, D., Kovach, J. S., Zhang, Q., Song, Q., Marincola, F. M., Heiss, J. D., Gilbert, M. R., Lu, R., & Zhuang, Z.
- Venue
- Nature Communications
- Published
- 2018-05-29
- Volume
- 9
- Issue
- 1
- Pages
- 2126-2126
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2806646910
- Cited by
- 93
- References
- 8
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. https://app.cochat.ai/papers/10.1038/s41467-018-04425-z
- The paper
- Ho, W. S., Wang, H., Maggio, D., Kovach, J. S., Zhang, Q., Song, Q., Marincola, F. M., Heiss, J. D., Gilbert, M. R., Lu, R., & Zhuang, Z. (2018). Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nature Communications. https://doi.org/10.1038/s41467-018-04425-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.